http://orcid.org/0000-0002-4483-0394
References
- Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.
- Kasamon YL, de Claro RA, Wang Y, et al. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma. Oncologist. 2017;22(5):585–591.
- Heinzerling L, Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol. 2017;29(2):136–144.
- Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709–718.
- Vogrig A, Fouret M, Joubert B, et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e604.
- Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.
- Möhn N, Beutel G, Gutzmer R, et al. Neurological immune-related adverse events associated with nivolumab, ipilimumab, and pembrolizumab. Therapy-review of the literature and future outlook. JCM. 2019;8(11):1777.
- Matsuoka H, Kimura H, Koba H, et al. Nivolumab-induced limbic encephalitis with anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer. 2018;19(5):e597–e599.
- Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634–642.
- Thummalapalli R, Sena LA, Probasco JC, et al. Checkpoint inhibitor-induced autoimmune encephalitis reversed by rituximab after allogeneic bone marrow transplant in a patient with Hodgkin lymphoma. Leuk Lymphoma. 2020;61(1):228–230.
- Chung M, Jaffer M, Verma N, et al. Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. J Neurol. 2019; [Dec 13].
- Shibaki R, Murakami S, Oki K, et al. Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient. Jpn J Clin Oncol. 2019;49(8):793–794.
- Guevara C, Farias G, Silva-Rosas C, et al. Encephalitis associated to metabotropic glutamate receptor 5 (mGluR5) antibodies in cerebrospinal fluid. Front Immunol. 2018;9:2568.
- Graus F, Escudero D, Oleaga L, et al. Syndrome and outcome of antibody-negative limbic encephalitis. Eur J Neurol. 2018;25(8):1011–1016.
- Rathore GS, Leung KS, Muscal E. Autoimmune encephalitis following bone marrow transplantation. Pediatr Neurol. 2015;53(3):253–256.